Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Study sponsor: Exelixis
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-08Estimated
Enrollment · participants600Estimated
Source updated2025-08-17Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.